» Articles » PMID: 32691484

Vascular Dysfunction in Aged Mice Contributes to Persistent Lung Fibrosis

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease thought to result from impaired lung repair following injury and is strongly associated with aging. While vascular alterations have been associated with IPF previously, the contribution of lung vasculature during injury resolution and fibrosis is not well understood. To compare the role of endothelial cells (ECs) in resolving and non-resolving models of lung fibrosis, we applied bleomycin intratracheally to young and aged mice. We found that injury in aged mice elicited capillary rarefaction, while injury in young mice resulted in increased capillary density. ECs from the lungs of injured aged mice relative to young mice demonstrated elevated pro-fibrotic and reduced vascular homeostasis gene expression. Among the latter, Nos3 (encoding the enzyme endothelial nitric oxide synthase, eNOS) was transiently upregulated in lung ECs from young but not aged mice following injury. Young mice deficient in eNOS recapitulated the non-resolving lung fibrosis observed in aged animals following injury, suggesting that eNOS directly participates in lung fibrosis resolution. Activation of the NO receptor soluble guanylate cyclase in human lung fibroblasts reduced TGFβ-induced pro-fibrotic gene and protein expression. Additionally, loss of eNOS in human lung ECs reduced the suppression of TGFβ-induced lung fibroblast activation in 2D and 3D co-cultures. Altogether, our results demonstrate that persistent lung fibrosis in aged mice is accompanied by capillary rarefaction, loss of EC identity, and impaired eNOS expression. Targeting vascular function may thus be critical to promote lung repair and fibrosis resolution in aging and IPF.

Citing Articles

Multiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease.

Leonard-Duke J, Agro S, Csordas D, Bruce A, Eggertsen T, Tavakol T PNAS Nexus. 2024; 4(1):pgae551.

PMID: 39720203 PMC: 11667245. DOI: 10.1093/pnasnexus/pgae551.


Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis.

Raslan A, Pham T, Lee J, Kontodimas K, Tilston-Lunel A, Schmottlach J Nat Commun. 2024; 15(1):5449.

PMID: 38937456 PMC: 11211333. DOI: 10.1038/s41467-024-49545-x.


Cell Cross-Talk in Alveolar Microenvironment: From Lung Injury to Fibrosis.

Song L, Li K, Chen H, Xie L Am J Respir Cell Mol Biol. 2024; 71(1):30-42.

PMID: 38579159 PMC: 11225874. DOI: 10.1165/rcmb.2023-0426TR.


Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.

Leonard-Duke J, Agro S, Csordas D, Bruce A, Eggertsen T, Tavakol T bioRxiv. 2024; .

PMID: 38559112 PMC: 10979947. DOI: 10.1101/2024.03.15.585249.


MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.

Fortier S, Walker N, Penke L, Baas J, Shen Q, Speth J J Clin Invest. 2024; 134(10).

PMID: 38512415 PMC: 11093610. DOI: 10.1172/JCI172826.


References
1.
Ng B, Dong J, DAgostino G, Viswanathan S, Widjaja A, Lim W . Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med. 2019; 11(511). DOI: 10.1126/scitranslmed.aaw1237. View

2.
Thomas D, Liu X, Kantrow S, Lancaster Jr J . The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci U S A. 2001; 98(1):355-60. PMC: 14594. DOI: 10.1073/pnas.98.1.355. View

3.
Loganathan K, Salem Said E, Winterrowd E, Orebrand M, He L, Vanlandewijck M . Angiopoietin-1 deficiency increases renal capillary rarefaction and tubulointerstitial fibrosis in mice. PLoS One. 2018; 13(1):e0189433. PMC: 5749705. DOI: 10.1371/journal.pone.0189433. View

4.
Nolan D, Ginsberg M, Israely E, Palikuqi B, Poulos M, James D . Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell. 2013; 26(2):204-19. PMC: 3873200. DOI: 10.1016/j.devcel.2013.06.017. View

5.
Kazakov A, Hall R, Jagoda P, Bachelier K, Muller-Best P, Semenov A . Inhibition of endothelial nitric oxide synthase induces and enhances myocardial fibrosis. Cardiovasc Res. 2013; 100(2):211-21. DOI: 10.1093/cvr/cvt181. View